- |||||||||| rivastigmine / Generic mfg.
Preclinical, Journal: Assessment of Anti-Alzheimer Pursuit of Jambolan Fruit Extract and/or Choline against AlCl Toxicity in Rats. (Pubmed Central) - Jun 27, 2023
Group 4: Rivastigmine (RIVA) aqueous infusion (0.3 mg/kg BW/day) was given orally to rats as a reference drug concomitantly with oral supplementation of AlCl (17 mg/kg body weight) for 28 days...The results showed that Jambolan fruit extract and choline chloride improved brain functions, histopathology, and antioxidant enzyme activity compared with the positive group. In conclusion, administering jambolan fruit extract and choline can lower the toxic impacts of aluminum chloride on the brain.
- |||||||||| donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
Review: Effect of Acetylcholinesterase Inhibitors on Cerebral Perfusion and Cognition: A Systematic Review. (Pubmed Central) - Jun 20, 2023
AChEIs appear to be a potential perfusion modifier in neurodegenerative patients. More research focused on quantitative perfusion in both patients with and without a cholinergic deficit is needed to draw conclusions on whether AChEI intake should be considered when analyzing perfusion data.
- |||||||||| risperidone / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
Review, Journal: Acetylcholinesterase inhibitors for autistic spectrum disorders. (Pubmed Central) - Jun 6, 2023
There is a need for more evidence of improvement in outcomes of relevance to clinical care, autistic people, and their families. There are a number of ongoing studies involving acetylcholinesterase inhibitors, and future updates of this review may add to the current evidence.
- |||||||||| blarcamesine (Anavex 2-73) / Anavex, Huntexil (pridopidine) / Prilenia, Elayta (CT1812) / Cognition Therap
Review, Journal: Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders. (Pubmed Central) - May 29, 2023
Furthermore, several sigma-2 receptor ligands are under investigation, including CT1812, rivastigmine and SAS0132. This review aims to provide a current and up-to-date analysis of the current clinical and pre-clinical data of drugs with sigma receptor activities for treating neurological disease.
- |||||||||| APH1105 / Aphios
Review, Journal: Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications. (Pubmed Central) - May 27, 2023
Currently, no drugs for intranasal administration in ATD have marketing approval, with only three candidates, insulin, rivastigmine and APH-1105, being clinically investigated. Further studies with different candidates will eventually confirm the potential of the intranasal route of administration in the treatment of ATD.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Review, Journal: Alzheimer's disease: Molecular aspects and treatment opportunities using herbal drugs. (Pubmed Central) - May 24, 2023
Herbal and food intake is also important as preventive strategy and recently focus has also been placed on herbal drugs for treatment. This review focuses on the molecular aspects, pathogenesis and recent studies that signifies the potential of medicinal plants and their extracts or chemical constituents for the treatment of degenerative symptoms related to AD.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Journal: Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs) (Pubmed Central) - May 21, 2023
In Japan, DMTs have not yet been approved for treating AD; however, four drugs are currently available for symptomatic therapies, including cholinesterase inhibitors (ChEIs) such as donepezil for mild-to-severe dementia, galantamine and rivastigmine for mild-to-moderate dementia, and memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, for moderate-to-severe dementia. In this review, we describe the use of four symptomatic anti-AD drugs in clinical practice for AD.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Journal, Adverse events: Adverse Drug Event Profile Associated with Anti-dementia Drugs: Analysis of a Spontaneous Reporting Database. (Pubmed Central) - May 20, 2023
Bradycardia, loss of consciousness, falls, and syncope incidence were significantly diverse. The Kaplan-Meier curve results for the cumulative ADEs incidence showed that donepezil had the slowest onset, while galantamine, rivastigmine, and memantine had approximately the same timing of onset.
- |||||||||| rivastigmine / Generic mfg.
Journal: Rivastigmine Use in the Treatment of Antimuscarinic Delirium. (Pubmed Central) - May 19, 2023
The Kaplan-Meier curve results for the cumulative ADEs incidence showed that donepezil had the slowest onset, while galantamine, rivastigmine, and memantine had approximately the same timing of onset. No abstract available
- |||||||||| rivastigmine / Generic mfg., duloxetine / Generic mfg.
Trial completion date, Trial primary completion date: Quality Improvement and Practice Based Research in Neurology Using the EMR (clinicaltrials.gov) - Apr 28, 2023
P4, N=3300, Enrolling by invitation,
Regardless of whether anti-dementia drugs were used alone or in combination, attention should be paid to the occurrence of arrhythmias. Trial completion date: Dec 2021 --> Dec 2025 | Trial primary completion date: Oct 2021 --> Dec 2024
- |||||||||| carbidopa/levodopa / Generic mfg., rivastigmine / Generic mfg.
Spinocerebellar ataxia 21 and phenotypic variability within a single family (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_3280;
The father underwent treatment for parkinsonism with carbidopa-levodopa and was started on rivastigmine without improvement. Conclusions SCA21 is a slowly progressive autosomal dominant spinocerebellar ataxia with variable neurodevelopmental phenotypes including multiple movement disorders within the same variant.
- |||||||||| donepezil / Generic mfg., rivastigmine / Generic mfg.
What Comes First: The Diagnosis or the Pill? Evidence from Alzheimer (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_1416;
Conclusions SCA21 is a slowly progressive autosomal dominant spinocerebellar ataxia with variable neurodevelopmental phenotypes including multiple movement disorders within the same variant. Design/Methods Commercial and Medicare Advantage Prescription Drug enrollees in the Optum
- |||||||||| rivastigmine transdermal / Generic mfg., rivastigmine / Generic mfg.
Journal, HEOR, Real-world evidence, Real-world: Prescription of transdermal patches in Colombia: A real-world evidence study. (Pubmed Central) - Feb 14, 2023
The study findings suggest a critical need to minimize CAB to improve AD care. The high proportion of inappropriately prescribed transdermal patches should draw the attention of those responsible for health care to improve the training of physicians and create prescription quality verification systems.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Journal: Investigation of Cannabis sativa Phytochemicals as Anti-Alzheimer's Agents: An In Silico Study. (Pubmed Central) - Feb 11, 2023
On the other hand, Cannabinol C2 (BA = -9.2 kcal/mol, Ki = 4.32 mM) significantly inhibits Butyrylcholinesterase (BuChE) in comparison to Memantine (BA = -6.8 kcal/mol, Ki = 0.54 mM). This study sheds new light and opens new avenues for elucidating the role of bioactive compounds present in Cannabis sativa in treating Alzheimer's disease.
- |||||||||| rivastigmine / Generic mfg.
Preclinical, Journal: Cationic biopolymer decorated Asiatic Acid and Centella asiatica extract incorporated liposomes for treating early-stage Alzheimer's disease: An In-vitro and In-vivo investigation. (Pubmed Central) - Feb 10, 2023
This study sheds new light and opens new avenues for elucidating the role of bioactive compounds present in Cannabis sativa in treating Alzheimer's disease. In the Alcl3-induced AD model in rats, disease progression was confirmed by Y-maze, the preliminary histopathology evaluation showed significantly higher efficacy of the prepared liposomes (CLCAE and CLAA) compared to the Centella asiatica extract (CAE) and they were found to have equivalent efficacy to the standard drug (rivastigmine tartrate)...The pharmacokinetic study, such as C , T , and area under curve (AUC) parameters, proved an increase in AA bioavailability in the form of CLAA compared to the pure AA and CLCAE forms.
- |||||||||| Kinaction (masitinib) / AB Science
Enrollment open: Masitinib in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Feb 6, 2023
P3, N=600, Recruiting,
In the Alcl3-induced AD model in rats, disease progression was confirmed by Y-maze, the preliminary histopathology evaluation showed significantly higher efficacy of the prepared liposomes (CLCAE and CLAA) compared to the Centella asiatica extract (CAE) and they were found to have equivalent efficacy to the standard drug (rivastigmine tartrate)...The pharmacokinetic study, such as C , T , and area under curve (AUC) parameters, proved an increase in AA bioavailability in the form of CLAA compared to the pure AA and CLCAE forms. Not yet recruiting --> Recruiting
- |||||||||| memantine / Generic mfg., rivastigmine / Generic mfg.
Journal: Anti-dementia drugs: a descriptive study of the prescription pattern in Italy. (Pubmed Central) - Jan 4, 2023
From a regulatory perspective, ADDs can be reimbursed by the National Health System only to patients diagnosed with AD; therefore, the off-label use of ADDs in patients with mild cognitive impairment may partially explain this phenomenon. The study extends knowledge on the use of ADDs, providing comparisons with studies from other countries that investigate the prescription pattern of ADDs.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Review, Journal: Role of multi-targeted bioactive natural molecules and their derivatives in the treatment of Alzheimer's disease: an insight into structure-activity relationship. (Pubmed Central) - Dec 30, 2022
This review summarises the structural properties required for bioactive natural molecules to show anti-Alzheimer's activity by emphasizing on SAR of several bioactive natural molecules targeting various AD pathologies, their key molecular interactions that are critical for target specificity, their role as multitargeted ligands, used with adjunctive therapy for AD followed by related US patents granted recently. This article highlights the significance of the structural features of natural bioactive molecules in the treatment of AD and establishes a connection between them.Communicated by Ramaswamy H. Sarma.
- |||||||||| rivastigmine / Generic mfg.
INTERFERENCE OF RIVASTIGMINE WITH TAU AGGREGATION INHIBITOR ACTIVITY AT THE SYNAPSE IN TAUTRANSGENIC MICE. (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1744;
This article highlights the significance of the structural features of natural bioactive molecules in the treatment of AD and establishes a connection between them.Communicated by Ramaswamy H. Sarma. The chronic neuronal activation of the brain with rivastigmine produces compensatory homeostatic chang es in the synapse that weakens/abolishes their sensitivity to hydromethylthionine.
- |||||||||| donepezil / Generic mfg., rivastigmine / Generic mfg.
A NOVEL SPICE-ANTIOXIDANT-BASED NANO-VEHICLE IN PREVENTION OF AD PATHOGENESIS (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1394;
The chronic neuronal activation of the brain with rivastigmine produces compensatory homeostatic chang es in the synapse that weakens/abolishes their sensitivity to hydromethylthionine. The antioxidants exhibited significant AChE inhibition ( in vitro ) individually (1, 8 -cineole exhibited least IC 50 of 65.53
- |||||||||| rivastigmine / Generic mfg.
Review, Journal: Alzheimer's Disease: Understanding Its Novel Drug Delivery Systems and Treatments. (Pubmed Central) - Dec 17, 2022
Therefore, better management and therapy are crucial. In this overview, we will briefly go through the current knowledge base about AD, covering the functions of beta-amyloid, tau proteins, and stem cell therapy, and elaborating on novel diagnostic and therapeutic interventions.
- |||||||||| Aduhelm (aducanumab) / Eisai, Biogen
Review, Journal: Conventional Versus New Treatment: Comparing the Effects of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonist With Aducanumab. (Pubmed Central) - Dec 8, 2022
Furthermore, memantine, an NMDA receptor antagonist, is authorized for moderate-to-severe dementia...Unfortunately, at this time, aducanumab's risks outweigh the benefits with a questionable approval process by the Food and Drug Administration (FDA). However, given the potential disease-modifying capabilities of aducanumab, other disease-modifying options may become available by possibly reducing inflammation, preventing Aβ plaques from clumping, or keeping tau proteins from tangling.
- |||||||||| Cognex (tacrine) / Shionogi
Journal: Recent developments in tacrine-based hybrids as a therapeutic option for Alzheimer's disease. (Pubmed Central) - Dec 6, 2022
Here, tacrine-based derivatives including heterocyclic structures such as dihydroxypyridine, chromene, coumarin, pyrazole, triazole, tetrahydroquinolone, dipicolylamine, arylisoxazole were reported with promising anti-AD effects compared to tacrine. In vitro and in vivo assays showed that new tacrine-based hybrids, which are selective, neuroprotective, and non-hepatotoxic, might be considered as remarkable anti-AD drug candidates for further clinical studies.
- |||||||||| rivastigmine / Generic mfg., gentamicin sulfate / Generic mfg.
Journal: Rivastigmine ameliorates gentamicin experimentally induced acute renal toxicity. (Pubmed Central) - Dec 4, 2022
RIVA showed a prompt improvement in the histopathological renal damage and a decrease in NF-κB immunoexpression. In conclusion, RIVA protective effects against GNT-induced AKI are mediated by decreasing GNT concentration in renal tissue and other effects like antioxidant and antiapoptotic effects possibly through its cholinergic anti-inflammatory action.
- |||||||||| donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
Journal, Real-world evidence: Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer´s dementia. (Pubmed Central) - Nov 19, 2022
Patients were primarily exposed to donepezil (65.8%) with rivastigmine (19.8%) and galantamine (14.4%) being used less often. These findings underscore the effect of AChEI on not only reducing speed of cognitive decline but also directly prolonging life, which could result in changes in treatment recommendation for when to stop treatment.
|
